Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial
13th May 2026 Uncategorised 0
Responders achieved weight loss and improvements in physical function

More: Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial
Source: News
